MX2024011079A - Regimenes extendidos, con dosis altas de antagonistas de vegf para el tratamiento de trastornos oculares angiogenicos - Google Patents

Regimenes extendidos, con dosis altas de antagonistas de vegf para el tratamiento de trastornos oculares angiogenicos

Info

Publication number
MX2024011079A
MX2024011079A MX2024011079A MX2024011079A MX2024011079A MX 2024011079 A MX2024011079 A MX 2024011079A MX 2024011079 A MX2024011079 A MX 2024011079A MX 2024011079 A MX2024011079 A MX 2024011079A MX 2024011079 A MX2024011079 A MX 2024011079A
Authority
MX
Mexico
Prior art keywords
treatment
extended
high dose
vegf antagonist
eye disorders
Prior art date
Application number
MX2024011079A
Other languages
English (en)
Spanish (es)
Inventor
Robert L Vitti
Alyson J Berliner
Karen Chu
Friedrich Asmus
Silva Leal Sergio Casimiro Da
Thomas Eissing
Kay D Rittenhouse
Original Assignee
Regeneron Pharma
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA3190733A external-priority patent/CA3190733A1/en
Application filed by Regeneron Pharma, Bayer Healthcare Llc filed Critical Regeneron Pharma
Publication of MX2024011079A publication Critical patent/MX2024011079A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2024011079A 2022-03-15 2024-09-10 Regimenes extendidos, con dosis altas de antagonistas de vegf para el tratamiento de trastornos oculares angiogenicos MX2024011079A (es)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202263319869P 2022-03-15 2022-03-15
US202263404512P 2022-09-07 2022-09-07
US202263404893P 2022-09-08 2022-09-08
US202263411594P 2022-09-29 2022-09-29
US202263412165P 2022-09-30 2022-09-30
US202263421298P 2022-11-01 2022-11-01
US202263434920P 2022-12-22 2022-12-22
US202363444480P 2023-02-09 2023-02-09
US202363447582P 2023-02-22 2023-02-22
CA3190733A CA3190733A1 (en) 2022-03-15 2023-02-22 Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
PCT/US2023/015225 WO2023177691A1 (en) 2022-03-15 2023-03-14 Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders

Publications (1)

Publication Number Publication Date
MX2024011079A true MX2024011079A (es) 2024-12-06

Family

ID=85704021

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024011079A MX2024011079A (es) 2022-03-15 2024-09-10 Regimenes extendidos, con dosis altas de antagonistas de vegf para el tratamiento de trastornos oculares angiogenicos

Country Status (13)

Country Link
US (1) US20240024420A1 (enExample)
EP (1) EP4245312A1 (enExample)
JP (1) JP2023135646A (enExample)
KR (1) KR20230135013A (enExample)
CN (1) CN119136823A (enExample)
AU (2) AU2023233561A1 (enExample)
CA (1) CA3253640A1 (enExample)
CL (2) CL2024002733A1 (enExample)
IL (1) IL315374A (enExample)
JO (1) JOP20240202A1 (enExample)
MX (1) MX2024011079A (enExample)
TW (1) TW202400214A (enExample)
WO (1) WO2023177691A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
FI4185318T3 (fi) 2021-05-17 2025-10-13 Regeneron Pharma Pitkäaikaisia, suuren annoksen VEGF-antagonistihoitoja angiogeenisten silmäsairauksien hoitoon
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
CN121712520A (zh) 2023-06-23 2026-03-20 瑞泽恩制药公司 用于治疗血管生成性眼病的延长的高剂量vegf拮抗剂方案
WO2025217334A1 (en) * 2024-04-09 2025-10-16 Regeneron Pharmaceuticals, Inc. Low concentration vegf receptor fusion protein containing formulations
KR20260096819A (ko) * 2024-12-13 2026-06-24 리제너론 파아마슈티컬스, 인크. 망막 정맥 폐쇄에 속발하는 혈관신생 눈 장애의 치료를 위한 연장된 고용량 vegf 길항제 레지먼

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
AR046510A1 (es) 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
ES2381014T3 (es) 2004-06-08 2012-05-22 Chengdu Kanghong Biotechnologies Co., Ltd. Proteína quimérica inhibidora de la angiogénesis y el uso
CN100502945C (zh) 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Vegf受体融合蛋白在治疗眼睛疾病中的应用
IL318292A (en) 2017-12-13 2025-03-01 Regeneron Pharma Devices and methods for administering precise doses
RS67656B1 (sr) 2018-05-10 2026-02-27 Regeneron Pharma Formulacije koje sadrže visoke koncentracije fuzionog proteina vegf receptora
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
AU2020326243A1 (en) * 2019-08-06 2022-02-17 F. Hoffmann-La Roche Ag Personalized treatment of ophthalmologic diseases
FI4185318T3 (fi) * 2021-05-17 2025-10-13 Regeneron Pharma Pitkäaikaisia, suuren annoksen VEGF-antagonistihoitoja angiogeenisten silmäsairauksien hoitoon

Also Published As

Publication number Publication date
AU2023201638A1 (en) 2023-10-05
EP4245312A1 (en) 2023-09-20
TW202400214A (zh) 2024-01-01
IL315374A (en) 2024-11-01
JOP20240202A1 (ar) 2024-09-09
CL2025001818A1 (es) 2025-10-03
KR20230135013A (ko) 2023-09-22
US20240024420A1 (en) 2024-01-25
JP2023135646A (ja) 2023-09-28
CL2024002733A1 (es) 2025-02-21
CN119136823A (zh) 2024-12-13
CA3253640A1 (en) 2023-09-21
WO2023177691A1 (en) 2023-09-21
AU2023233561A1 (en) 2024-09-19

Similar Documents

Publication Publication Date Title
CL2024002733A1 (es) Regímenes extendidos, con dosis altas de antagonistas de vegf para el tratamiento de trastornos oculares angiogénicos.
CL2024002718A1 (es) Regímenes extendidos, con dosis altas de antagonistas de vegf para el tratamiento de trastornos oculares angiogénicos.
CL2023003396A1 (es) Regímenes de antagonistas del vegf en dosis alta extendidos para el tratamiento de trastornos oculares angiogénicos.
MX2013007847A (es) Uso de un antagonista de factor de crecimiento endotelial vascular para tratar transtornos oculares angiogenicos.
EA202090019A1 (ru) Спироциклические индолины в качестве модуляторов il-17
MX2021001439A (es) Composiciones y metodos para el tratamiento de la disfuncion de la glandula de meibomio.
CO2021014008A2 (es) Compuestos farmacéuticos para el tratamiento de trastornos mediados por complemento
MX385368B (es) Metodos para el tratamiento de trastornos del movimiento involuntario anormal.
AR092860A1 (es) Formulacion oftalmica y metodo para mejorar la presbicia
CL2020001047A1 (es) Derivados de imidazol condensado sustituidos por grupos de hidroxia terciaria como inhibidores pi3k-gamma.
MX394388B (es) Compuestos de tetrahidroquinolinona sustituidos como moduladores de ror gamma
UY37774A (es) Compuestos 5-cianoindol sustituidos y usos de los mismos
BR112015023694A2 (pt) entrega craniana de fármacos
NI201600091A (es) UREAS ASIMÉTRICAS p-SUSTITUIDAS Y USOS MÉDICOS DE LAS MISMAS
MX2020012014A (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
IT201600103956A1 (it) Formulazione oftalmica comprendente citicolina veicolata da liposomi per il trattamento del glaucoma
CO2024011399A2 (es) Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa
MX2018008272A (es) Compuestos antagonizantes del receptor a3 de la adenosina, metodo para prepararlos y uso medico de los mismos.
JOP20250312A1 (ar) جرعة عالية ممتدة من نظم علاجية لمضاد vegf لعلاج اضطرابات العين وعائية المنشأ
CA3297204A1 (en) Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
EA201790231A1 (ru) Профилактическое или терапевтическое средство для лечения болезней заднего сегмента глаза